Test dell'aggiunta della radioterapia al trattamento abituale (immunoterapia con o senza chemioterapia) per i pazienti con carcinoma polmonare non a piccole cellule in stadio IV che sono negativi per PD-L1
Uno studio randomizzato di fase II/III della moderna terapia sistemica basata sull'immunoterapia con o senza SBRT per carcinoma polmonare non a piccole cellule avanzato, PD-L1-negativo
This phase II/III trial compares the addition of radiation therapy to the usual treatment (immunotherapy with or without chemotherapy) versus (vs.) usual treatment alone in treating patients with non-small cell lung cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic) whose tumor is also negative for a molecular marker called PD-L1. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill tumor cells and shrink tumors. Immunotherapy with monoclonal antibodies, such as nivolumab, ipilimumab may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The addition of radiation therapy to usual treatment may stop the cancer from growing and increase the life of patients with advanced non-small cell lung cancer who are PD-L1 negative.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
- Altro: Quality-of-Life Assessment
- Procedura: Biospecimen Collection
- Biologico: Ipilimumab
- Procedura: Computed Tomography
- Procedura: Magnetic Resonance Imaging
- Procedura: Echocardiography Test
- Procedura: Positron Emission Tomography
- Biologico: Nivolumab
- Radiazione: Radiation Therapy
- Procedura: Biopsy Procedure
Descrizione dettagliata
PRIMARY OBJECTIVE:
I. To assess if radiation improves the progression free survival (PFS, phase II portion) and overall survival (OS, phase III portion) of advanced stage non-small cell lung cancer (NSCLC) patients with PD-L1 tumor proportion score (TPS) < 1% who receive immunotherapy with or without chemotherapy.
SECONDARY OBJECTIVES:
I. To estimate and compare the rates of >= grade 3-4 and all grade adverse events by Common Terminology Criteria for Adverse Events (CTCAE) version (v)5.0 between the arms.
II. To summarize and compare progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) between the arms.
III. To determine and compare the objective response rate (ORR) per RECIST between the arms (including at both irradiated and un-irradiated sites).
QUALITY OF LIFE (QOL) OBJECTIVE:
I. To assess the health-related QOL in both treatment arms.
CORRELATIVE SCIENCE OBJECTIVE:
I. To evaluate changes in the peripheral immune microenvironment between the arms.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM A: Patients receive nivolumab intravenously (IV) over 30 minutes on days 1 and 22 and ipilimumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 6 weeks for 24 months in the absence of disease progression or unacceptable toxicity or patients may receive standard of care systemic immunotherapy. Patients also undergo magnetic resonance imaging (MRI), computed tomography (CT), or positron emission tomography (PET) throughout the trial. Patients may undergo blood sample collection and tissue biopsy on study as well as echocardiography (ECHO) during screening.
Arm B: Patients receive nivolumab IV over 30 minutes on days 1 and 22 and ipilimumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 6 weeks for 24 months in the absence of disease progression or unacceptable toxicity or patients may receive standard of care systemic immunotherapy. Patients also undergo 3 fractions of radiation therapy every other day. Patients also undergo MRI, CT, or PET throughout the trial. Patients may undergo blood sample collection and tissue biopsy on study as well as ECHO during screening.
After completion of study treatment, patients are followed up every 3 months for 3 years and then every 6 months for years 4-5 following randomization until disease progression. Following disease progression patients are followed for survival every 6 months for up to 5 years following randomization.
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Fase 2
- Fase 3
Contatti e Sedi
Luoghi di studio
-
-
Arizona
-
Phoenix, Arizona, Stati Uniti, 85054
- Mayo Clinic Hospital in Arizona
-
-
Arkansas
-
Little Rock, Arkansas, Stati Uniti, 72205
- University of Arkansas for Medical Sciences
-
-
California
-
Berkeley, California, Stati Uniti, 94704
- Alta Bates Summit Medical Center-Herrick Campus
-
Duarte, California, Stati Uniti, 91010
- City of Hope Comprehensive Cancer Center
-
Irvine, California, Stati Uniti, 92618
- City of Hope at Irvine Lennar
-
Lancaster, California, Stati Uniti, 93534
- City of Hope Antelope Valley
-
Marysville, California, Stati Uniti, 95901
- Fremont - Rideout Cancer Center
-
Modesto, California, Stati Uniti, 95355
- Memorial Medical Center
-
Napa, California, Stati Uniti, 94558
- Providence Queen of The Valley
-
Sacramento, California, Stati Uniti, 95817
- University of California Davis Comprehensive Cancer Center
-
South Pasadena, California, Stati Uniti, 91030
- City of Hope South Pasadena
-
Truckee, California, Stati Uniti, 96161
- Gene Upshaw Memorial Tahoe Forest Cancer Center
-
Upland, California, Stati Uniti, 91786
- City of Hope Upland
-
-
Colorado
-
Colorado Springs, Colorado, Stati Uniti, 80909
- UCHealth Memorial Hospital Central
-
Colorado Springs, Colorado, Stati Uniti, 80920
- Memorial Hospital North
-
Fort Collins, Colorado, Stati Uniti, 80524
- Poudre Valley Hospital
-
Fort Collins, Colorado, Stati Uniti, 80528
- Cancer Care and Hematology-Fort Collins
-
Greeley, Colorado, Stati Uniti, 80631
- UCHealth Greeley Hospital
-
Loveland, Colorado, Stati Uniti, 80538
- Medical Center of the Rockies
-
-
Delaware
-
Millville, Delaware, Stati Uniti, 19967
- Beebe South Coastal Health Campus
-
Newark, Delaware, Stati Uniti, 19713
- Helen F Graham Cancer Center
-
Newark, Delaware, Stati Uniti, 19713
- Medical Oncology Hematology Consultants PA
-
Rehoboth Beach, Delaware, Stati Uniti, 19971
- Beebe Health Campus
-
-
District of Columbia
-
Washington D.C., District of Columbia, Stati Uniti, 20010
- MedStar Washington Hospital Center
-
-
Florida
-
Aventura, Florida, Stati Uniti, 33180
- UM Sylvester Comprehensive Cancer Center at Aventura
-
Clearwater, Florida, Stati Uniti, 33756
- Morton Plant Hospital
-
Coral Gables, Florida, Stati Uniti, 33146
- UM Sylvester Comprehensive Cancer Center at Coral Gables
-
Deerfield Beach, Florida, Stati Uniti, 33442
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach
-
Miami, Florida, Stati Uniti, 33136
- University of Miami Miller School of Medicine-Sylvester Cancer Center
-
Miami, Florida, Stati Uniti, 33176
- UM Sylvester Comprehensive Cancer Center at Kendall
-
Plantation, Florida, Stati Uniti, 33324
- UM Sylvester Comprehensive Cancer Center at Plantation
-
Tampa, Florida, Stati Uniti, 33607
- Saint Joseph's Hospital/Children's Hospital-Tampa
-
Winter Haven, Florida, Stati Uniti, 33881
- Winter Haven Hospital
-
-
Georgia
-
Newnan, Georgia, Stati Uniti, 30265
- CTCA at Southeastern Regional Medical Center
-
Savannah, Georgia, Stati Uniti, 31405
- Lewis Cancer and Research Pavilion at Saint Joseph's/Candler
-
-
Idaho
-
Boise, Idaho, Stati Uniti, 83712
- Saint Luke's Cancer Institute - Boise
-
Fruitland, Idaho, Stati Uniti, 83619
- Saint Luke's Cancer Institute - Fruitland
-
Meridian, Idaho, Stati Uniti, 83642
- Saint Luke's Cancer Institute - Meridian
-
Nampa, Idaho, Stati Uniti, 83687
- Saint Luke's Cancer Institute - Nampa
-
Twin Falls, Idaho, Stati Uniti, 83301
- Saint Luke's Cancer Institute - Twin Falls
-
-
Illinois
-
Chicago, Illinois, Stati Uniti, 60611
- Northwestern University
-
Chicago, Illinois, Stati Uniti, 60637
- University of Chicago Comprehensive Cancer Center
-
Chicago, Illinois, Stati Uniti, 60612
- University of Illinois
-
Danville, Illinois, Stati Uniti, 61832
- Carle at The Riverfront
-
DeKalb, Illinois, Stati Uniti, 60115
- Northwestern Medicine Cancer Center Kishwaukee
-
Decatur, Illinois, Stati Uniti, 62526
- Decatur Memorial Hospital
-
Effingham, Illinois, Stati Uniti, 62401
- Crossroads Cancer Center
-
Effingham, Illinois, Stati Uniti, 62401
- Carle Physician Group-Effingham
-
Geneva, Illinois, Stati Uniti, 60134
- Northwestern Medicine Cancer Center Delnor
-
Glenview, Illinois, Stati Uniti, 60026
- Northwestern Medicine Glenview Outpatient Center
-
Grayslake, Illinois, Stati Uniti, 60030
- Northwestern Medicine Grayslake Outpatient Center
-
Harvey, Illinois, Stati Uniti, 60426
- Ingalls Memorial Hospital
-
Lake Forest, Illinois, Stati Uniti, 60045
- Northwestern Medicine Lake Forest Hospital
-
Mattoon, Illinois, Stati Uniti, 61938
- Carle Physician Group-Mattoon/Charleston
-
New Lenox, Illinois, Stati Uniti, 60451
- UC Comprehensive Cancer Center at Silver Cross
-
O'Fallon, Illinois, Stati Uniti, 62269
- HSHS Saint Elizabeth's Hospital
-
Orland Park, Illinois, Stati Uniti, 60462
- University of Chicago Medicine-Orland Park
-
Rockford, Illinois, Stati Uniti, 61114
- UW Health Carbone Cancer Center Rockford
-
Springfield, Illinois, Stati Uniti, 62702
- Southern Illinois University School of Medicine
-
Springfield, Illinois, Stati Uniti, 62702
- Springfield Clinic
-
Springfield, Illinois, Stati Uniti, 62781
- Springfield Memorial Hospital
-
Urbana, Illinois, Stati Uniti, 61801
- Carle Cancer Center
-
Warrenville, Illinois, Stati Uniti, 60555
- Northwestern Medicine Cancer Center Warrenville
-
-
Indiana
-
Crown Point, Indiana, Stati Uniti, 46307
- UChicago Medicine Northwest Indiana
-
-
Iowa
-
Ames, Iowa, Stati Uniti, 50010
- Mary Greeley Medical Center
-
Ames, Iowa, Stati Uniti, 50010
- McFarland Clinic - Ames
-
Ankeny, Iowa, Stati Uniti, 50023
- UI Health Care Mission Cancer and Blood - Ankeny Clinic
-
Clive, Iowa, Stati Uniti, 50325
- Mercy Cancer Center-West Lakes
-
Clive, Iowa, Stati Uniti, 50325
- UI Health Care Mission Cancer and Blood - West Des Moines Clinic
-
Creston, Iowa, Stati Uniti, 50801
- Greater Regional Medical Center
-
Des Moines, Iowa, Stati Uniti, 50309
- Iowa Methodist Medical Center
-
Des Moines, Iowa, Stati Uniti, 50314
- Mercy Medical Center - Des Moines
-
Des Moines, Iowa, Stati Uniti, 50309
- UI Health Care Mission Cancer and Blood - Des Moines Clinic
-
Des Moines, Iowa, Stati Uniti, 50314
- UI Health Care Mission Cancer and Blood - Laurel Clinic
-
Waukee, Iowa, Stati Uniti, 50263
- UI Health Care Mission Cancer and Blood - Waukee Clinic
-
West Des Moines, Iowa, Stati Uniti, 50266
- Mercy Medical Center-West Lakes
-
West Des Moines, Iowa, Stati Uniti, 50266
- The Iowa Clinic PC
-
-
Kentucky
-
Lexington, Kentucky, Stati Uniti, 40536
- University of Kentucky/Markey Cancer Center
-
Lexington, Kentucky, Stati Uniti, 40509
- CommonSpirit Saint Joseph Medical Center - East Lexington
-
-
Maine
-
Sanford, Maine, Stati Uniti, 04073
- MaineHealth Cancer Care Center of York County
-
Scarborough, Maine, Stati Uniti, 04074
- MaineHealth Maine Medical Center- Scarborough
-
South Portland, Maine, Stati Uniti, 04106
- MaineHealth Cancer Care and IV Therapy - South Portland
-
-
Michigan
-
Ann Arbor, Michigan, Stati Uniti, 48106
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor
-
Brighton, Michigan, Stati Uniti, 48114
- Trinity Health IHA Medical Group Hematology Oncology - Brighton
-
Brighton, Michigan, Stati Uniti, 48114
- Trinity Health Medical Center - Brighton
-
Canton, Michigan, Stati Uniti, 48188
- Trinity Health IHA Medical Group Hematology Oncology - Canton
-
Canton, Michigan, Stati Uniti, 48188
- Trinity Health Medical Center - Canton
-
Chelsea, Michigan, Stati Uniti, 48118
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
-
Chelsea, Michigan, Stati Uniti, 48118
- Chelsea Hospital
-
Flint, Michigan, Stati Uniti, 48503
- Hurley Medical Center
-
Flint, Michigan, Stati Uniti, 48503
- Genesys Hurley Cancer Institute
-
Kalamazoo, Michigan, Stati Uniti, 49007
- West Michigan Cancer Center
-
Kalamazoo, Michigan, Stati Uniti, 49007
- Bronson Methodist Hospital
-
Lansing, Michigan, Stati Uniti, 48912
- University of Michigan Health - Sparrow Lansing
-
Livonia, Michigan, Stati Uniti, 48154
- Trinity Health Saint Mary Mercy Livonia Hospital
-
Pontiac, Michigan, Stati Uniti, 48341
- Trinity Health Saint Joseph Mercy Oakland Hospital
-
Pontiac, Michigan, Stati Uniti, 48341
- Michigan Healthcare Professionals Pontiac
-
Saginaw, Michigan, Stati Uniti, 48604
- Oncology Hematology Associates of Saginaw Valley PC
-
Saginaw, Michigan, Stati Uniti, 48601
- MyMichigan Medical Center Saginaw
-
Tawas City, Michigan, Stati Uniti, 48764
- MyMichigan Medical Center Tawas
-
West Branch, Michigan, Stati Uniti, 48661
- Saint Mary's Oncology/Hematology Associates of West Branch
-
Ypsilanti, Michigan, Stati Uniti, 48197
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
-
-
Minnesota
-
Duluth, Minnesota, Stati Uniti, 55805
- Miller-Dwan Hospital
-
Minneapolis, Minnesota, Stati Uniti, 55415
- Hennepin County Medical Center
-
Robbinsdale, Minnesota, Stati Uniti, 55422
- North Memorial Medical Health Center
-
Saint Cloud, Minnesota, Stati Uniti, 56303
- Coborn Cancer Center at Saint Cloud Hospital
-
Saint Paul, Minnesota, Stati Uniti, 55101
- Regions Hospital
-
-
Missouri
-
Cape Girardeau, Missouri, Stati Uniti, 63703
- Saint Francis Medical Center
-
Farmington, Missouri, Stati Uniti, 63640
- Parkland Health Center - Farmington
-
Rolla, Missouri, Stati Uniti, 65401
- Phelps Health Delbert Day Cancer Institute
-
Sainte Genevieve, Missouri, Stati Uniti, 63670
- Sainte Genevieve County Memorial Hospital
-
Springfield, Missouri, Stati Uniti, 65804
- Mercy Hospital Springfield
-
St Louis, Missouri, Stati Uniti, 63131
- Missouri Baptist Medical Center
-
St Louis, Missouri, Stati Uniti, 63141
- Mercy Hospital Saint Louis
-
St Louis, Missouri, Stati Uniti, 63128
- Mercy Hospital South
-
Sullivan, Missouri, Stati Uniti, 63080
- Missouri Baptist Sullivan Hospital
-
-
Montana
-
Bozeman, Montana, Stati Uniti, 59715
- Bozeman Health Deaconess Hospital
-
-
New York
-
Buffalo, New York, Stati Uniti, 14263
- Roswell Park Cancer Institute
-
Lake Success, New York, Stati Uniti, 11042
- Northwell Health/Center for Advanced Medicine
-
New York, New York, Stati Uniti, 10019
- Mount Sinai West
-
New York, New York, Stati Uniti, 10029
- Mount Sinai Hospital
-
New York, New York, Stati Uniti, 10011
- Mount Sinai Chelsea
-
New York, New York, Stati Uniti, 10075
- Lenox Hill Hospital
-
New York, New York, Stati Uniti, 10065
- Manhattan Eye Ear and Throat Hospital
-
Oswego, New York, Stati Uniti, 13126
- Upstate Cancer Center at Oswego
-
Oswego, New York, Stati Uniti, 13126
- Upstate Cancer Center Radiation Oncology at Oswego
-
Syracuse, New York, Stati Uniti, 13210
- State University of New York Upstate Medical University
-
Syracuse, New York, Stati Uniti, 13215
- SUNY Upstate Medical Center-Community Campus
-
Syracuse, New York, Stati Uniti, 13210
- Upstate Cancer Center at Hill Radiation Oncology
-
Verona, New York, Stati Uniti, 13478
- Upstate Cancer Center at Verona
-
-
North Carolina
-
Durham, North Carolina, Stati Uniti, 27710
- Duke University Medical Center
-
Raleigh, North Carolina, Stati Uniti, 27609
- Duke Cancer Center Raleigh
-
Winston-Salem, North Carolina, Stati Uniti, 27157
- Wake Forest University Health Sciences
-
-
Ohio
-
Akron, Ohio, Stati Uniti, 44304
- Summa Health System - Akron Campus
-
-
Oklahoma
-
Lawton, Oklahoma, Stati Uniti, 73505
- Cancer Centers of Southwest Oklahoma Research
-
Oklahoma City, Oklahoma, Stati Uniti, 73104
- University of Oklahoma Health Sciences Center
-
Oklahoma City, Oklahoma, Stati Uniti, 73120
- Mercy Hospital Oklahoma City
-
-
Oregon
-
Gresham, Oregon, Stati Uniti, 97030
- Legacy Mount Hood Medical Center
-
Portland, Oregon, Stati Uniti, 97239
- Oregon Health and Science University
-
Portland, Oregon, Stati Uniti, 97210
- Legacy Good Samaritan Hospital and Medical Center
-
Tualatin, Oregon, Stati Uniti, 97062
- Legacy Meridian Park Hospital
-
-
Pennsylvania
-
Chadds Ford, Pennsylvania, Stati Uniti, 19317
- Christiana Care Health System-Concord Health Center
-
Danville, Pennsylvania, Stati Uniti, 17822
- Geisinger Medical Center
-
Hershey, Pennsylvania, Stati Uniti, 17033-0850
- Penn State Milton S Hershey Medical Center
-
Lewisburg, Pennsylvania, Stati Uniti, 17837
- Geisinger Medical Oncology-Lewisburg
-
Reading, Pennsylvania, Stati Uniti, 19605
- Penn State Health Saint Joseph Medical Center
-
Wilkes-Barre, Pennsylvania, Stati Uniti, 18711
- Geisinger Wyoming Valley/Henry Cancer Center
-
-
South Carolina
-
Charleston, South Carolina, Stati Uniti, 29425
- Medical University of South Carolina
-
-
Texas
-
Amarillo, Texas, Stati Uniti, 79106
- The Don and Sybil Harrington Cancer Center
-
-
Virginia
-
Richmond, Virginia, Stati Uniti, 23235
- VCU Massey Cancer Center at Stony Point
-
Richmond, Virginia, Stati Uniti, 23298
- VCU Massey Comprehensive Cancer Center
-
Tappahannock, Virginia, Stati Uniti, 22560
- VCU Health Tappahannock Hospital
-
-
Washington
-
Vancouver, Washington, Stati Uniti, 98686
- Legacy Salmon Creek Hospital
-
Vancouver, Washington, Stati Uniti, 98684
- Legacy Cancer Institute Medical Oncology and Day Treatment
-
Walla Walla, Washington, Stati Uniti, 99362
- Providence Saint Mary Regional Cancer Center
-
-
West Virginia
-
Charleston, West Virginia, Stati Uniti, 25304
- Vandalia Health/CAMC Institute for Academic Medicine
-
-
Wisconsin
-
Ashland, Wisconsin, Stati Uniti, 54806
- Northwest Wisconsin Cancer Center
-
Eau Claire, Wisconsin, Stati Uniti, 54701
- Marshfield Medical Center-EC Cancer Center
-
La Crosse, Wisconsin, Stati Uniti, 54601
- Gundersen Lutheran Medical Center
-
La Crosse, Wisconsin, Stati Uniti, 54601
- Mayo Clinic Health System-Franciscan Healthcare
-
Marshfield, Wisconsin, Stati Uniti, 54449
- Marshfield Medical Center-Marshfield
-
Minocqua, Wisconsin, Stati Uniti, 54548
- Marshfield Medical Center - Minocqua
-
Mukwonago, Wisconsin, Stati Uniti, 53149
- ProHealth D N Greenwald Center
-
New Richmond, Wisconsin, Stati Uniti, 54017
- Cancer Center of Western Wisconsin
-
Oconomowoc, Wisconsin, Stati Uniti, 53066
- ProHealth Oconomowoc Memorial Hospital
-
Rice Lake, Wisconsin, Stati Uniti, 54868
- Marshfield Medical Center-Rice Lake
-
Stevens Point, Wisconsin, Stati Uniti, 54482
- Marshfield Medical Center-River Region at Stevens Point
-
Waukesha, Wisconsin, Stati Uniti, 53188
- UW Cancer Center at ProHealth Care
-
Weston, Wisconsin, Stati Uniti, 54476
- Marshfield Medical Center - Weston
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Histologic or cytologic diagnosis of stage IV NSCLC using version American Joint Committee on Cancer (AJCC) 8th edition (includes M1a, M1b, and M1c stage disease). Patients with stage IIIB and IIIC disease are eligible if they are not a candidate for combined chemotherapy and radiation
- PD-L1 expression tumor proportion score (TPS) < 1% in tumor cells. If PD-L1 expression TPS is unevaluable or the testing could not be completed patients are not eligible. The assay must have been performed locally by a Clinical Laboratory Improvement Act (CLIA) (or equivalent) certified laboratory. The type of assay will be recorded
- For non-squamous patients only (adenocarcinoma or adenosquamous): EGFR, ALK and ROS1 testing must be done locally. No patients with known actionable EGFR mutations (except exon 20 insertion), ALK or ROS1 mutations that can be treated with oral tyrosine inhibitors
- Measurable disease based on RECIST 1.1, including at least two cancerous deposits. At least one deposit must be RECIST measurable (and not to be irradiated) while at least one OTHER deposit (measurable or non-measurable) must meet criteria for three 8 gray (Gy) doses of radiation
- Age >= 18 years
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- No more than three weeks of treatment with systemic chemotherapy or immunotherapy for advanced NSCLC
- No more than three weeks of treatment with checkpoint inhibitors for metastatic lung cancer
- No treatment with chemotherapy or immunotherapy for non-metastatic disease (e.g., adjuvant therapy) within 6 months prior to registration
- No systemic immunostimulatory or immunosuppressive drugs, including > 10 mg prednisone equivalent per day, within 2 weeks or 5 half-live of the drug, whichever is shorter. Steroid premedication per local standard is allowed
- >= 1 week prior to registration since palliative (including central nervous system [CNS]) radiotherapy to any tumor site
- No prior allogeneic tissue/solid organ transplant
- No uncontrolled intercurrent illness including, but not limited to, serious ongoing or active infection, symptomatic congestive heart failure, uncontrolled cardiac arrhythmia, unstable angina pectoris, that would limit compliance with study requirements
- No current pneumonitis or history of non-infectious pneumonitis that required steroids
- Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of registration
- No active auto-immune disease that requires systemic therapy within 2 years prior to registration. Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid release therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed
- No known history of hepatitis B (defined as hepatitis B surface antigen [HBsAg] reactive) or known hepatitis C virus (defined as HCV ribonucleic acid [RNA] [qualitative] is detected) infection
- No patients with symptomatic central nervous system metastases and/or carcinomatous meningitis. Patients with small asymptomatic brain metastases are eligible as are patients with treated brain metastases that require no steroids
- Not pregnant and not nursing, because this study involves radiation as well as potentially chemotherapy which have known genotoxic, mutagenic and teratogenic effects. Therefore, for women of childbearing potential only, a negative urine or serum pregnancy test done =< 7 days prior to registration is required
- No patients with a "currently active" second malignancy that is progressing or has required active treatment within the last 2 years. Participants with non-melanoma skin cancers or carcinoma in-situ (e.g., breast carcinoma, urothelial carcinoma or cervical cancer in situ) or localized prostate cancer (T1-3, N0, M0) that have undergone potentially curative therapy are eligible
- No hypersensitivity (>= grade 3) to immunotherapy and/or any of its excipients
- No live vaccine within 30 days prior to registration. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guerin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g.,FluMist [registered trademark]) are live attenuated vaccines and are not allowed. COVID-19 vaccine is allowed
- Absolute neutrophil count (ANC) >= 1,500/mm^3
- Platelet count >= 100,000/mm^3
- Calculated (Calc.) creatinine clearance >= 45 mL/min
- Total bilirubin =< 1.5 x upper limit of normal (ULN)
- Aspartate aminotransferase (AST) / alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN)
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Arm A (immunotherapy, +/- chemotherapy)
Patients receive nivolumab intravenously (IV) over 30 minutes on days 1 and 22 and ipilimumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 6 weeks for 24 months in the absence of disease progression or unacceptable toxicity or patients may receive standard of care systemic immunotherapy. Patients also undergo MRI, CT, or PET throughout the trial. Patients may undergo blood sample collection and tissue biopsy on study as well as ECHO during screening. |
Ancillary studies
Altri nomi:
Undergo blood sample collection
Altri nomi:
Given IV
Altri nomi:
Undergo CT
Altri nomi:
Undergo MRI
Altri nomi:
Undergo ECHO
Altri nomi:
Undergo PET
Altri nomi:
Given IV
Altri nomi:
Undergo tissue biopsy
Altri nomi:
|
|
Sperimentale: Arm B (immunotherapy, +/- chemotherapy, radiation therapy)
Patients receive 1 of 6 treatment options as in Arm A. Patients also undergo 3 fractions of radiation therapy every other day. Patients also undergo MRI, CT, or PET throughout the trial. Patients may undergo blood sample collection and tissue biopsy on study as well as ECHO during screening. |
Ancillary studies
Altri nomi:
Undergo blood sample collection
Altri nomi:
Given IV
Altri nomi:
Undergo CT
Altri nomi:
Undergo MRI
Altri nomi:
Undergo ECHO
Altri nomi:
Undergo PET
Altri nomi:
Given IV
Altri nomi:
Undergo radiation therapy
Altri nomi:
Undergo tissue biopsy
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Progression-free survival (PFS) (Phase II)
Lasso di tempo: From randomization to disease progression or death of all causes, whichever comes first, assessed up to 5 years
|
Will be performed on an intent-to-treat (ITT) basis. |
From randomization to disease progression or death of all causes, whichever comes first, assessed up to 5 years
|
|
Overall survival (OS) (Phase III)
Lasso di tempo: From randomization and death of all causes, assessed up to 5 years
|
Will be performed on an ITT basis. The comparison of the distributions of OS between treatment arms will be done with a one-sided stratified log-rank test). The rates at various time points (e.g., every 6 months after randomization) and medians of OS for each arm will be estimated using the Kaplan-Meier estimator. The associated 95% confidence interval (CI) will be calculated using Greenwood's formula and based on a log-log transformation applied on the survival function. Hazard ratios will be estimated using a stratified Cox regression model. The final phase III analysis of OS will be considered as "positive" if the stratified log-rank test statistics Z-value greater than the critical value adjusted for type 1 error using group sequential methods. Multivariable Cox models will be used to evaluate the treatment effect on survival time and its interaction with baseline covariates, including stage, systemic therapy, histology and performance status. |
From randomization and death of all causes, assessed up to 5 years
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Qualità della vita
Lasso di tempo: Fino a 5 anni
|
Fino a 5 anni
|
|
|
PFS
Lasso di tempo: From randomization to disease progression or death of all causes, whichever comes first, assessed up to 5 years
|
Assessed per Response Evaluation Criteria in Solid Tumors (RECIST). |
From randomization to disease progression or death of all causes, whichever comes first, assessed up to 5 years
|
|
Objective response rate (ORR)
Lasso di tempo: Up to 5 years
|
Assessed per RECIST for both irradiated and un-irradiated areas. The ORRs between treatments will be compared with Fisher's exact test. The difference of ORR between treatments will be estimated by the Miettinen-Nurminen method and its 95% CI will be given. Multivariable logistic regression will be used to evaluate the treatment effect on ORR while adjusting for significant baseline covariates. |
Up to 5 years
|
|
Incidence of treatment-related adverse events
Lasso di tempo: Up to 5 years
|
Treatment-related toxicity will be summarized by grade, type, and system organ class. Comparisons of the percentages of patients experiencing an adverse event between Arm A and Arm B will be performed using Fisher's exact test. |
Up to 5 years
|
Collaboratori e investigatori
Sponsor
Sponsor
Investigatori
Investigatori
- Investigatore principale: Christine M Bestvina, Alliance for Clinical Trials in Oncology
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Neoplasie per sede
- Neoplasie
- Malattie delle vie respiratorie
- Neoplasie per tipo istologico
- Malattie polmonari
- Neoplasie, ghiandolari ed epiteliali
- Adenocarcinoma
- Neoplasie delle vie respiratorie
- Neoplasie toraciche
- Carcinoma
- Carcinoma, broncogeno
- Neoplasie bronchiali
- Adenocarcinoma del polmone
- Neoplasie polmonari
- Carcinoma, polmone non a piccole cellule
- Aminoacidi, peptidi e proteine
- Proteine
- Tecniche investigative
- Terapie
- Tecniche di laboratorio clinico
- Tecniche e procedure diagnostiche
- Diagnosi
- Procedure chirurgiche, operative
- Tecniche citologiche
- Citodiagnosi
- Fattori biologici
- Fenomeni fisici
- Anticorpi, monoclonali, umanizzati
- Anticorpi, monoclonali
- Anticorpi
- Immunoglobuline
- Immunoproteine
- Proteine del sangue
- Globuline sieriche
- Globuline
- Tecniche diagnostiche, chirurgiche
- Tecniche di chimica, analitiche
- Analisi dello spettro
- Recettori, superficie cellulare
- Proteine della membrana
- Antigeni
- Antigeni, superficie
- Biomarcatori
- Recettori, immunologici
- Antigeni, differenziazione, T-linfocita
- Antigeni, differenziazione
- Proteine del checkpoint immunitario
- Recettori costimolativi e inibitori delle cellule T.
- Nivolumab
- Ipilimumab
- Radioterapia
- Radiazione
- Biopsia
- Gestione dei campioni
- Spettroscopia di risonanza magnetica
- Antigene CTLA-4
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- NCI-2021-06042
- U10CA180821 (Sovvenzione/contratto NIH degli Stati Uniti)
- NCI-2021-06042 (Identificatore di registro: CTRP (Clinical Trial Reporting Program))
- A082002 (Altro identificatore: CTEP)
- A082002 (Altro identificatore: Alliance for Clinical Trials in Oncology)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .